Abstract:Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are related intestinal L-cell derived secretory products. GLP-1 has been extensively studied in terms of its influence on metabolism, but less attention has been devoted to GLP-2 in this regard. The current study compares the effects of these proglucagon-derived peptides on pancreatic beta-cell function, as well as on glucose tolerance and appetite. The insulin secretory effects of GLP-1 and GLP-2 (10−12–10−6 M) were investigated in BRIN-BD11 beta-cells as well as isolated mouse islets, with the impact of test peptides (10 nM) on real-time cytosolic cAMP levels further evaluated in mouse islets. The impact of both peptides (10−8–10−6 M) on beta-cell growth and survival was also studied in BRIN BD11 cells. Acute in vivo (peptides administered at 25 nmol/kg) glucose homeostatic and appetite suppressive actions were then examined in healthy mice. GLP-1, but not GLP-2, concentration dependently augmented insulin secretion from BRIN-BD11 cells, with similar observations made in isolated murine islets. In addition, GLP-1 substantially increased [cAMP]cyt in islet cells and was significantly more prominent than GLP-2 in this regard. Both GLP-1 and GLP-2 promoted beta-cell proliferation and protected against cytokine-induced apoptosis. In overnight fasted healthy mice, as well as mice trained to eat for 3 h per day, the administration of GLP-1 or GLP-2 suppressed appetite. When injected conjointly with glucose, both peptides improved glucose disposal, which was associated with enhanced glucose-stimulated insulin secretion by GLP-1, but not GLP-2. To conclude, the impact of GLP-1 and GLP-2 on insulin secretion is divergent, but the effects of beta-cell signaling and overall health are similar. Moreover, the peripheral administration of either hormone in rodents results in comparable positive effects on blood glucose levels and appetite.

Molecular Mechanism of Glucagon-like Peptide 1 and Its Analogies Regulating the Proliferation of Β Cells

Molecular Mechanism of Glucagon Peptide-2 in Stimulating Cell Proliferation and Suppressing Cell Apoptosis

New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-catenin

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

The physiology of glucagon-like peptide 1

Advance in Studies on Glucagon-like Peptide-2

The Relation of Glucagon-Like Peptide-1 and Nutrients Metabolization

Glucagon-like Peptide 1 and Its Derivatives in the Treatment of Diabetes-preclinical and Clinical Results

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Control of insulin secretion by GLP-1

Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation

Glucagon-Like Skin-1’s Effect on Islet β Cells in High Glucose via AMPK/mTOR Pathway

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

Insulin Regulates Glucagon-Like Peptide-1 Secretion by Pancreatic Alpha Cells.

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Research Progress in the Effect Evaluation of GLP1-1 Agonists

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Evidence for Paracrine/autocrine Regulation of GLP-1-producing Cells.

Effect of glucagon-like peptide-1 for the treatment of diabetes mellitus